盘龙药业氟比洛芬贴剂获批临床试验 有望实现进口替代

Group 1 - The core product under development by the company, the flurbiprofen patch, has received approval for clinical trials from the National Medical Products Administration [1] - The flurbiprofen patch, developed by Taisho Pharmaceutical Co., Ltd., was first approved in Japan in July 1998 and is intended for pain relief and anti-inflammatory treatment for conditions such as osteoarthritis and muscle pain [1] - The product is classified as a Class 3 chemical drug and is considered an import substitute with clinical value, as the original drug is not yet available in the domestic market [1] Group 2 - The market for flurbiprofen topical formulations is significant, with sales of flurbiprofen gel patches projected to reach 2.839 billion yuan in 2024 and 2.350 billion yuan in the first three quarters of 2025 [2] - If the clinical trials for the flurbiprofen patch proceed successfully, it is expected to capture market share due to its technological advantages, creating a differentiated competitive landscape [2] - The company aims to enhance its product portfolio in the musculoskeletal field, complementing its core products and establishing a comprehensive "oral + topical" orthopedic solution, which will strengthen its brand and market barriers [2]